Company Overview of Receptos, Inc.
Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in immune disorders. Its lead product includes ozanimod, an oral therapy that is in phase III studies for the treatment of relapsing multiple sclerosis; and is in phase II studies to treat ulcerative colitis and crohn’s disease. The company is also developing RPC4046, a monoclonal antibody, which is in phase II trials for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that is in preclinical st...
3033 Science Park Road
San Diego, CA 92121
Founded in 2008
Key Executives for Receptos, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $451.6K
Chief Financial Officer and Principal Accounting Officer
Total Annual Compensation: $254.8K
Chief Medical officer
Total Annual Compensation: $364.3K
Compensation as of Fiscal Year 2013.
Receptos, Inc. Key Developments
Receptos, Inc. Presents at Barclays Global Healthcare Conference, Mar-12-2015 02:05 PM
Mar 9 15
Receptos, Inc. Presents at Barclays Global Healthcare Conference, Mar-12-2015 02:05 PM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States.
Receptos, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014
Mar 3 15
Receptos, Inc. reported consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported loss from operations of $37,159,000 against $15,099,000 a year ago. Net loss attributable to common stockholders was $38,151,000 or $1.32 per basic and diluted share against $15,244,000 or $0.86 per basic and diluted share a year ago.
For the full year, the company reported loss from operations of $111,570,000 against $47,893,000 a year ago. Net loss attributable to common stockholders was $114,970,000 or $4.63 per basic and diluted share against $50,376,000 or $4.23 per basic and diluted share a year ago. Collaborative revenue was $5,900,000 against $4,641,000 a year ago.
Receptos, Inc. to Report Q4, 2014 Results on Mar 03, 2015
Feb 26 15
Receptos, Inc. announced that they will report Q4, 2014 results at 5:00 PM, US Eastern Standard Time on Mar 03, 2015
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|